Business Wire

S-GROUP

10.5.2023 05:01:34 CEST | Business Wire | Press release

Share
Finnish Scientists Develop a Method for Corporations to Assess Their Biodiversity Footprint—an Internationally Groundbreaking Pilot Project Assessed S Group’s Impact on Nature

Researchers at the University of Jyväskylä have developed a method for corporations to calculate their biodiversity footprint. The pilot project focused on S Group’s biodiversity footprint. The outcome of the study will be a method freely available to all companies and organisations for the assessment of their impact on nature.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509005817/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Researchers at the University of Jyväskylä have developed a method for corporations to calculate their biodiversity footprint. The pilot project focused on S Group’s biodiversity footprint. (Photo: Business Wire)

The interim report of the project published now indicates that food and fuels account for most of S Group’s biodiversity footprint, with the majority of the footprint falling on regions beyond Finland’s borders. Utility goods account for a significantly smaller portion—a few per cent—of the biodiversity footprint.

“Companies already routinely calculate their carbon footprints. This project demonstrates that they can also calculate their biodiversity footprint. A company like S Group, with operations in several different sectors, played a key role in the method’s development,” says Janne Kotiaho, Professor of Ecology at the University of Jyväskylä.

“You have to tackle climate and biodiversity challenges hand in hand. As opposed to climate efforts, biodiversity impacts are very local. The report shows that there is a need for increasingly strong cooperation between businesses and partners operating within the same geographic area. Companies must also start building new kinds of cooperation networks to reduce their negative impact on nature,” says Nina Elomaa, Senior Vice President, Sustainability, at S Group.

“You cannot manage something that you can’t measure. Stopping biodiversity loss requires a functional method for calculating biodiversity footprints. Any company that intends to make a serious effort to manage their biodiversity impact needs a method of this kind. We can take some national pride in Finland being at the forefront of this global development work,” says Lasse Miettinen, Director of Sustainability solutions at Sitra.

The theme is topical, given that nations around the world agreed on new international targets for halting biodiversity loss at the Montreal Biodiversity Conference in December. The global biodiversity framework agreed on also stated that, in the future, large and transnational companies should disclose their negative impact on biodiversity.

Biodiversity footprint maps impact on terrestrial and aquatic ecosystems

Through complex supply chains, a large part of the negative environmental impact attributable to Finnish consumption is generated across the globe, beyond Finland’s borders. According to the calculation model based on financial accounting and Finland’s international trade, more than 90 per cent of S Group’s global biodiversity footprint falls on regions outside Finland.

S Group aims to reduce its biodiversity impact through its climate work and by promoting more sustainable consumption and a planetary health diet. Concrete actions include policies related to raw materials and sourcing that aims to protect fish populations, for example, or ensure that no purchases are made from areas sensitive in terms of forest loss.

How S Group’s biodiversity footprint was assessed

The biodiversity footprint of S Group’s value chain and own operations was assessed with a method devised by the University of Jyväskylä School of Resource Wisdom – JYU.Wisdom.

The indicator of the biodiversity footprint is the share of the world’s species at risk of extinction, i.e. the Potentially Disappeared Fraction (PDF) of species. The indicator collects the PDF of various species under a single unit of measurement, similar to carbon footprint assessments, and enables the international comparison of different corporations’ biodiversity footprints.

The method’s further development continues.

For more information:

S Group - S Group (s-ryhma.fi)
JYU.Wisdom − School of Resource Wisdom — University of Jyväskylä
The Finnish Innovation Fund Sitra

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005817/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye